Introduction {#Sec1}
============

Dysregulation of angiogenesis occurs in various pathologies and is one of the hallmarks for cancer. The importance of this biological process in normal hematopoietic cell development and the pathophysiology of several malignancies, including B cell chronic lymphocytic leukemia (B-CLL), has been recently reported \[[@CR1]--[@CR3]\]. Patients with CLL have been demonstrated to have detectable levels of both plasma and cellular pro- and anti-angiogenic cytokines, as well as abnormal neovascularization in the marrow and lymph nodes \[[@CR4]--[@CR6]\]. Recent evidence suggests that vascular endothelial growth factor (VEGF)-based autocrine pathway promotes the survival of CLL B cells in part through upregulation of anti-apoptotic proteins \[[@CR7]\]. Moreover, interactions between CLL B cells and their microenvironment generate alterations in the secretion of angiogenic factors that result in enhanced leukemic B cell resistance to apoptotic cell death \[[@CR8]\]. Among a variety of angiogenic factors involved in the CLL, vascular endothelial growth factor and basic fibroblast growth factor (bFGF) were identified \[[@CR9]\]. Their levels have been regarded as prognostic markers of the progression of the disease \[[@CR10]--[@CR14]\] in patients with B-CLL, including those of Polish origin. The data on the role of the VEGF and bFGF in CLL are summarized in Table [1](#Tab1){ref-type="table"}.Table 1Current status of data on the role of VEGF and bFGF in CLLFactorObservation/impact on the diseaseReferenceVEGFVEGF is expressed differently in plasma and serum of CLL patients\[[@CR1]\]VEGF mRNA and protein are produced in CLL cells\[[@CR4]\]VEGF is expressed on B-CLL granulocytes and lymphocytes; VEGF receptors, VEGFR-1 and VEGFR-2, are expressed on B-CLL cells\[[@CR6]\]VEGF levels do not differ between plasma of CLL patients and healthy controls\[[@CR5]\]Bone marrow stromal cells (BMSC) treated with CLL microvesicles produce VEGF on a higher level than untreated healthy BMSC, but not as high as CLL-BMSC;\[[@CR3]\]VEGF~165~ is the main and overexpressed isoform in CLL-BMSC compared to healthy cells;VEGF~121~ is poorly expressed, and isoforms VEGF~189~ and VEGF~206~ are not detectedVEGF serum level is higher in CLL patients than in healthy individuals;\[[@CR13]\]VEGF and VEGFR-2 levels are significantly higher in serum of patients in III or IV than in those in 0--II Rai stage of the disease;VEGF and VEGFR-2 serum levels correlate in CLL patientsVEGF supports antiapoptotic and cytoproliferative effect of CD154 in CLL cells;\[[@CR7]\]Inhibition of VEGF and its receptor decreases CLL cells survivalVEGF produced by bone marrow stromal cells, but not by CLL cells, decreases CLL cells apoptosis\[[@CR8]\]Increased expression of VEGF receptors correlates with clinical stage\[[@CR24]\]High serum levels of VEGF correlate with increased risk of disease progression in early B-CLL\[[@CR11]\]Low level of VEGF correlates with worse outcome in B-CLL patients with low level of β2-microglobulin (good prognosis indicator) what may lead to decreased survival of patients in 0 to II stadium of the disease\[[@CR12]\]Targeting VEGF receptors effectively induces apoptosis in primary CLL cells and reduces tumor growth in a VEGF-positive CLL-like xenograft mouse model\[[@CR25]\]bFGFPlasma levels of bFGF in CLL patients are significantly higher compared to levels of other proangiogenic molecules (i.e. VEGF) in plasma of these patients\[[@CR1]\]Plasma levels of bFGF are significantly higher in patients with B-CLL compared to healthy controls\[[@CR5]\]Serum levels of bFGF are statistically higher in patients with B-CLL than in healthy controls; serum bFGF level was significantly higher in patients with progressive than in those with stable disease\[[@CR14]\]bFGF upregulates BCL-2 expression in B-CLL\[[@CR9]\]Increased expression of bFGF correlates with clinical stage\[[@CR10]\]

The objective of the present study was to assess whether polymorphisms located within the genes coding for these key angiogenic activators (VEGF and bFGF), contribute to disease susceptibility and/or progression in patients with B-CLL.

Materials and methods {#Sec2}
=====================

Patients and controls {#Sec3}
---------------------

Sixty-eight patients (F/M = 27/41), aged 39--85 (median 69) years, with B-CLL were investigated. B-CLL was diagnosed according to defined clinical, morphological and immunological criteria. All patients gave their informed consent prior to their inclusion in the study. The study has been approved by the appropriate ethics committee.

Patients were treated at the Department of Hematology, Wroclaw Medical University. According to the modified Rai classification \[[@CR15]\], there were 17, 28 and 12 patients in stage 0, I and II of the disease, respectively. The other 11 patients presented with more advanced disease: 6 and 5 with stage III and IV, respectively. In addition, 112 healthy individuals of both sexes (F/M = 57/55) served as a control group.

*VEGF* and *bFGF* genotyping {#Sec4}
----------------------------

DNA was isolated from the whole blood taken on EDTA with the use of Qiagen DNA Isolation Kit (Qiagen GmbH, Hilden, Germany).

The *VEGF* and *bFGF* alleles were detected using a polymerase chain reaction restriction fragment length polymorphism (PCR--RFLP) assay.

In brief, DNA was extracted from peripheral blood taken on EDTA using silica membranes (QiAmp Blood Kit, Qiagen, Hilden, Germany) following the recommendations of the manufacturer. A 208-bp-long fragment of the 3′ untranslated region (UTR) of the *VEGF* gene was amplified using the following primers: forward, 5′-GAG TGT CCC TGA CAA CAC TGG CA-3′, reverse, 5′-AGC AGC AGA TAA GGG ACT GGG GA-3′ as previously described \[[@CR16]\]. The following primer pair was used for amplification of a 437-bp-long fragment of the *bFGF* gene promoter region: 5′-TGA GTT ATC CGA TGT CTG AAA TG-3′ and 5′-TAAC TTG AAT TAG ACG ACG CAG A-3′ \[[@CR17]\]. The PCR cycling conditions were as follows: 94 °C for 3 min, followed by 30 cycles of: 94 °C for 30 s, 60 °C for 30 s, 72 °C for 30 s, with a final elongation step at 72 °C for 7 min. The PCR products were analyzed by electrophoresis in a 2 % agarose gel with ethidium bromide and visualized under UV. Then, the PCR products specific for the *VEGF* and *bFGF* gene were digested with *Nla*III and *Bse*IV restriction endonucleases (New England BioLabs^®^ Inc.), respectively, and analyzed on an agarose gel. Electrophoresis demonstrated the original 208-bp fragment (homozygous individuals for the *VEGF C* allele, lacking the *Nla*III site), three fragments of 208, 122 and 86 bp in length (heterozygous individual) or two fragments of 122 and 88 bp (homozygous individual for the *VEGF T* variant). For the *bFGF* polymorphism, the following electrophoresis patterns were observed: the original 437-bp fragment (homozygous individuals for the *bFGF C* allele, lacking the *Bse*IV site), three fragments of 437, 370 and 67 bp in length (heterozygous individual) or two fragments of 370 and 67 bp (homozygous individual for the *bFGF G* variant).

Statistical analysis {#Sec5}
--------------------

Statistical evaluation was performed using Statistica 5.5 for Windows software. Genotype and allele frequencies were compared between the study groups by the Fisher's exact or Person's test. The Odds Ratio (OR) was calculated by Haldane's modification of Woolf's method, and the significance of its deviation from unity was estimated by Fisher's exact test. Survival analyses were performed employing Kaplan--Maier analysis and log rank test. Probability values \<0.05 were considered statistically significant, and those between 0.05 and 0.1 as indicative of a trend.

Results and discussion {#Sec6}
======================

The former studies on the role of the VEGF and bFGF in B-CLL regarded their serum levels or cellular expression as prognostic markers of the progression of the disease \[[@CR10]--[@CR14]\].

As for the Polish patients with CLL, our former study documented the significantly higher bFGF levels in B-CLL patients than in controls \[[@CR14]\], while Gora-Tybor et al. \[[@CR13]\] described the differences in VEGF serum levels between patients and controls, and patients in Rai stage III and IV versus those in Rai stage 0--II (summarized in Table [1](#Tab1){ref-type="table"}).

As VEGF production appeared to have a significant effect on the susceptibility to CLL and the course of the disease, in our present study, we wanted to determine whether functionally relevant polymorphism within the VEGF encoding gene (pp. 936 C \> T in the 3′-UTR) could contribute to the risk of this malignant disease. The previous reports documented significantly lower VEGF plasma levels in carriers of the *936 T* allele what could be attributed to the 936 C/T exchange leading to the loss of a potential binding site for transcription factor AP-4 (activating enhancer-binding protein 4) \[[@CR18]\].

The *bFGF (pp.* −*921 C* \> *G)* promoter polymorphism was also studied. Polymorphisms within the promoter region of the *bFGF* gene may interfere with existing transcription factor binding sites or produce new binding sites and therefore influence the *bFGF* gene expression \[[@CR17]\].

In the present study, C to T substitution at position 936 within the 3′-UTR of the *VEGF* gene and C to G substitution at position −921 within the promoter region of the *bFGF* gene were analyzed in order to determine whether the presence of these allelic variants is associated with susceptibility and progression of the disease in CLL patients.

As mentioned before, unfavorable CLL progression was reported to be associated with high VEGF levels and increased VEGF expression with a lack of the *VEGF 936 T* variant \[[@CR18]\]. That is why the less frequent representation of the *VEGF T* allele among patients, especially those presented with more advanced disease, was expected. However, only a slight prevalence of the *VEGF T* variant was observed among patients as compared to healthy individuals (20/68 vs. 20/112, OR = 1.91, *p* = 0.095, Table [2](#Tab2){ref-type="table"}). This relationship reached statistical significance when a group of high risk patients was considered. Among 11 patients in III or IV stage of the disease, 5 (45 %) were carrying the *T* allele as compared to 20 out of 112 (18 %) controls (OR = 3.81, *p* = 0.045, Table [2](#Tab2){ref-type="table"}).Table 2Patients characteristics with respect to the distribution of the *VEGF T* and *bFGF G* variants in comparison with healthy populationCLL patients*NVEGF pp. 936bFGF pp.* −*921TCCGCC*n (%)n (%)n (%)n (%)Sex, F/M Female27111642331 %59 %15 %85 % Male4193283321 %78 %19.5 %80.5 %Stage of the disease (Rai) Low risk  01761141335 %65 %24 %76 % Intermediate  I/II28/1293163422.5 %77.5 %15 %85 % High risk  III/IV6/55^c^62945.5 %54.5 %18 %82 %Serum β2-microglobulin^a^ Normal1551021323 %67 %13 %87 % Elevated3192232829 %71 %10 %90 %Patients6820^b^48125629 %71 %18 %82 %Healthy individuals11220^b,c^92229018 %82 %20 %80 %The *VEGF T* variant was more frequently detected among patients presented with stage III/IV disease (high risk group). Individuals carrying the *VEGF T* variant are over three times more likely to develop high risk B-CLL*CLL* chronic lymphocytic leukemia^a^Elevated \>1.80 mg/L, unknown for 22 cases^b^(CLL patients vs. controls) OR = 1.91, *p* = 0.095^c^(high risk patients vs. controls) OR = 3.82, *p* = 0.045

No other significant association was observed between the *VEGF* polymorphism and progression of the disease. The *VEGF* alleles and genotypes segregated similarly in patients with different stage of the disease according to Rai classification, beta2 microglobulin serum level and survival.

No other significant relationships were also observed for the *bFGF* polymorphism with either susceptibility to B-CLL (when compared to control group, Table [2](#Tab2){ref-type="table"}) or progression of the disease.

Thus, no differences in *VEGF* and/or bFGF alelle and/or genotype distribution were noted between subgroups with stage 0--II versus III--IV according to modified Rai staging as well as males versus females (individual data not shown).

Intensive literature search was performed in order to compare the *VEGF* and *bFGF* alleles and genotypes distribution in Caucasian B-CLL patients and controls of other studies with our present results.

To our knowledge, there are no published data on the role of *VEGF* and *bFGF* polymorphisms in B-CLL (thus, our report present novel observations not previously described).

As for the *bFGF* gene polymorphism, similar distributions of *bFGF* alleles and genotypes in healthy Czech (*n* = 126) \[[@CR17]\] and Slovenian (*n* = 107) \[[@CR19]\], (*n* = 294) \[[@CR20]\] were shown.

There were more studies investigating the distribution of the *VEGF* alleles showing comparable results. Allele frequencies of the present study are in agreement with those previously published for healthy Caucasians \[[@CR21]--[@CR23]\].

These data suggest that while the *bFGF (*−*921 C* \> *G)* polymorphism does not significantly contribute to susceptibility and progression of the disease in Polish patients with B-CLL, the *VEGF (936 C* \> *T)* polymorphism may be associated with high risk disease.

Obviously, these results should be regarded as preliminary and confirmed in the more extended study, including patients from the other centers.
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